

Article Corrected

Nguyen CM, Bounthavong M, Mendes MAS, Christopher MLD, Tran JN, Kazerooni R, Morreale AP. Cost utility of tumour necrosis factor- α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model. *Pharmacoeconomics* 2012; 30 (7): 575-93

Corrections Made

The authors have reported a number of corrections to their analysis following the Letter to the Editor by Diamantopoulos et al.^[1] These corrections have not affected the conclusions of the article but have resulted in a number of changes to the cost and utility results presented throughout the text, figures and tables. In addition, a wider range of utility values were tested in the one-way sensitivity analyses as the corrections resulted in a wider variance than previously reported. Please refer to Bounthavong et al.'s reply^[2] to Diamantopoulos et al. for a more comprehensive explanation of these errors and to the online corrected version for correct cost and utility results.

Note

All online versions of this article have been updated to reflect the authors' corrections.

References

1. Diamantopoulos A, Sawyer L, Ogale S, et al. Validity of cost and utility results? [letter]. *Pharmacoeconomics* 2012; 30 (10): 977
2. Bounthavong M, Nguyen CM, Mendes MAS, et al. The authors' reply [letter]. *Pharmacoeconomics* 2012; 30 (10): 977-8